Key result
Deep hypothermic circulatory arrest shows no 90-day mortality benefit in RCC with atrial thrombus.
Why the study?
Outcomes of surgery for renal cell carcinoma with tumor thrombus invading the right atrium and the impact of deep hypothermic circulatory arrest were unclear in Japanese patients.
Does deep hypothermic circulatory arrest improve perioperative outcomes and survival in patients with renal cell carcinoma undergoing surgery for right atrial tumor thrombus?
Cohort (n=23)
Yes
Does deep hypothermic circulatory arrest improve perioperative outcomes and survival in patients with renal cell carcinoma undergoing surgery for right atrial tumor thrombus?
In patients with renal cell carcinoma and right atrial tumor thrombus, extracorporeal circulation-assisted surgery provides acceptable long-term survival, with comparable outcomes regardless of the use of deep hypothermic circulatory arrest.
Comparable mortality does not support routine arrest use; leaves open optimal strategy for renal cell carcinoma with atrial thrombus.
OBJECTIVES: To evaluate the outcomes of Japanese patients with renal cell carcinoma undergoing surgery for tumor thrombus invading the right atrium. METHODS: We retrospectively evaluated 23 patients who underwent extracorporeal circulation-assisted surgery at two institutions. Perioperative outcomes and survival rates were evaluated and compared between two groups of patients, which were set according to the use or not of deep hypothermic circulatory arrest. Data on systemic treatments were assessed. RESULTS: The median age was 64 years; the majority of patients were fit according to the Charlson Comorbidity Index. Five (21.7%) patients had at least one distant metastasis, and 17 (73.9%) received systemic therapy. A total of 16 (69.6%) patients underwent deep hypothermic circulatory arrest. Baseline characteristics were comparable between groups. Patients who underwent deep hypothermic circulatory arrest had a non-significant reduction in blood loss compared with those who did not undergo this procedure (1866.0 vs 3513.0 mL, P = 0.102). The complication rate, both of any grade (43.8% vs 71.4%, P = 0.215) and grade ≥3 (6.3% vs 28.6%, P = 0.162), tended to be lower in patients who underwent deep hypothermic circulatory arrest. The mean 90-day mortality rate was 8.7%, with no difference among groups (6.3% vs 14.3%, respectively; P = 0.545). The overall median cancer-specific and overall survival were both 64.4 months, and did not differ between groups. CONCLUSIONS: Renal cell carcinoma patients undergoing extracorporeal circulation-assisted surgery and systemic therapy for right atrial tumor thrombus have acceptable long-term survival rates. Outcomes are comparable regardless of the use of deep hypothermic circulatory arrest.
No takes yet. Share an insight, caveat, or question.
Ishiyama et al. (2021) conducted a cohort in Renal cell carcinoma with right atrial tumor thrombus (n=23). Deep hypothermic circulatory arrest vs. No deep hypothermic circulatory arrest was evaluated on 90-day mortality (p=0.545). Deep hypothermic circulatory arrest during surgery for renal cell carcinoma with right atrial thrombus resulted in similar 90-day mortality compared to no arrest (6.3% vs 14.3%; P=0.545).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: